ANIX - NASDAQ

Anixa Biosciences, Inc.

ANIX·NASDAQ

$2.61

+3.6%

HealthcareBiotechnology

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$87.51M

EPS-0.3400

P/E Ratio-7.68

Earnings Date06/03/2026

16.08M

Assets

-26%

3Y-47.0%

5Y+70.0%

10Y+186.0%

2.13M

Total Liabilities

-21%

3Y-4.0%

5Y+79.0%

10Y-54.0%

13.95M

Total Equity

-26%

3Y-51.0%

5Y+69.0%

10Y+1313.0%

Anixa Biosciences, Inc. Funding & Solvency Profile

ANIX · NASDAQ

Current Assets

Cash & Cash Equivalents1.24M

Net Receivables0.00

Inventory0.00

Other Current Assets713.00K

Total Current Assets16 M

Non-Current Assets

Property, Plant & Equipment193.00K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets193 K

Total Assets

16.08M

Financial Health Analysis

Current Ratio

8.08x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.15x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

14 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

99% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Anixa Biosciences, Inc. Balance Sheet

ANIX • NASDAQ

Anixa Biosciences, Inc. Balance Sheet	Oct 2025	Oct 2024	Oct 2023	Oct 2022	Oct 2021	Oct 2020	Oct 2019	Oct 2018	Oct 2017	Oct 2016	Oct 2015	Oct 2014	Oct 2013	Oct 2012	Oct 2011	Oct 2010	Oct 2009	Oct 2008	Oct 2007	Oct 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	1.2M	1.3M	915K	12.4M	29.1M	6.4M	3.5M	3.1M	3.3M	2.5M	4.4M	3.4M	898.2K	339.7K	774K	1.1M	1.5M	478.6K	669.1K	1.3M
Short-Term Investments	13.9M	18.7M	22.9M	17.3M	6.6M	2.6M	2.4M	2M	3.5M	750K	2.4M	2.5M	0.0	500K	2.2M	0.0	749.9K	1.4M	400K	38K
Cash & Short-Term Investments	15.2M	19.9M	23.8M	29.7M	35.7M	9.1M	5.8M	5.1M	6.8M	3.2M	6.8M	5.9M	898.2K	839.7K	3M	1.1M	2.2M	1.9M	1.1M	1.3M
Net Receivables	0.0	173K	270K	46K	0.0	2.2K	66.5K	307K	0.0	0.0	0.0	400K	175K	0.0	0.0	-140.8K	750.0	103K	120K	10.2K
Accounts Receivables	0.0	173K	270K	46K	0.0	2.2K	66.5K	307K	0.0	0.0	0.0	400K	175K	0.0	0.0	0.0	750.0	103K	120K	10.2K
Inventory	0.0	0.0	0.0	-46K	0.0	0.0	-2.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	52K	132.7K	178.1K	191.9K	260.8K
Prepaids	0.0	0.0	0.0	467K	276K	311.6K	185K	175.5K	174.6K	162.1K	126.5K	60.6K	160.6K	82.3K	97.2K	140.8K	62.6K	54.3K	34.6K	32K
Other Current Assets	713K	1.3M	1.2M	46K	-444.0	-2.2K	0.0	0.0	0.0	0.0	0.0	0.0	160.6K	0.0	0.0	88.8K	61.9K	0.0	0.0	0.0
Total Current Assets	15.9M	21.4M	25.4M	30.2M	36M	9.4M	6.1M	5.5M	7M	3.4M	6.9M	6.3M	1.2M	922K	3.1M	1.2M	2.4M	2.3M	1.4M	1.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	193K	229K	166K	212K	254K	54.3K	200.6K	72.7K	52.7K	156.6K	43.5K	11.9K	8.4K	10.3K	15.9K	14.9K	21.2K	29.8K	26.7K	23.1K
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	837.5K	1.7M	2.1M	2.4M	2.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	837.5K	1.7M	2.1M	2.4M	2.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2M	4.7M	5.5M	8.8M	7.4M	0.0	0.0	0.0
Other Non-Current Assets	0.0	0.0	0.0	0.0	0.0	30K	-200.6K	0.0	0.0	0.0	0.0	0.0	0.0	-4.7M	0.0	0.0	0.0	5.2M	427.9K	217.9K
Total Non-Current Assets	193K	229K	166K	212K	254K	84.3K	200.6K	910.2K	1.8M	2.2M	2.4M	2.7M	4.2M	4.7M	5.5M	8.8M	7.5M	5.2M	454.5K	241K
Total Assets	16.1M	21.6M	25.5M	30.4M	36.3M	9.5M	6.3M	6.4M	8.8M	5.6M	9.3M	9.1M	5.4M	5.7M	8.6M	10M	9.8M	7.5M	1.9M	1.9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	165K	525K	206K	265K	136K	232.4K	585.8K	582K	480.3K	373.2K	374.7K	540.2K	527.2K	304.5K	374.7K	355.7K	326.2K	384.9K	347.1K	532.7K
Accounts Payable	165K	525K	206K	265K	136K	232.4K	585.8K	582K	480.3K	373.2K	374.7K	540.2K	527.2K	304.5K	374.7K	355.7K	326.2K	384.9K	347.1K	532.7K
Accrued Expenses	839K	1.9M	1.8M	1.7M	1.1M	901K	72.9K	63K	51.6K	95.5K	6.1K	372.8K	345.5K	103.5K	54.7K	62.9K	35.7K	35.5K	289.6K	10.9K
Short Term Debt	41K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	29K	52K	46K	39K	55.2K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2M	1.2M	1.6M	0.0	0.0	313.3K	0.0	0.0
Other Current Liabilities	922K	0.0	0.0	0.0	0.0	0.0	822.6K	620.1K	357.5K	0.0	213K	896.6K	1.2M	227.2K	31K	31.6K	34.2K	33.8K	42.1K	38.2K
Total Current Liabilities	2M	2.5M	2M	2M	1.3M	1.2M	1.5M	1.3M	889.5K	468.8K	593.8K	1.8M	3.2M	1.8M	2.1M	450.1K	396.2K	767.6K	678.8K	581.8K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5M	5M	0.0	0.0	0.0	5M	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	482.7K	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	82.0	0.0	0.0	0.0	0.0	4.2M	3.7M	3.2M	0.0	0.0	5M	5M	5M	0.0	0.0	0.0
Total Non-Current Liabilities	163K	203K	123K	175K	220.1K	0.0	0.0	582K	480.3K	4.2M	3.7M	3.2M	5.5M	5M	5.5M	5M	5M	5M	347.1K	532.7K
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-582K	-480.3K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-347.1K	-532.7K
Capital Lease Obligations	163K	232K	175K	221K	259K	55.2K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	2.1M	2.7M	2.2M	2.2M	1.5M	1.2M	1.5M	1.3M	889.5K	4.6M	4.3M	5M	8.8M	6.9M	7.6M	5.5M	5.4M	5.8M	678.8K	581.8K
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	-6K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	35.7K	14K	14K	350K	1.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	330K	322K	311K	309K	300.5K	242.5K	203.3K	189.1K	166K	87.5K	87.2K	2.2M	2.1M	1.8M	1.8M	1.5M	1.4M	1.3M	1.1M	992.6K
Additional Paid-In Capital	266.5M	260.4M	252.2M	247.1M	239.9M	200.4M	186.8M	175.4M	163.9M	152.1M	151.1M	146.2M	134.8M	127.7M	125.1M	120.1M	116.3M	109.3M	86.1M	80.8M
Retained Earnings	-251.7M	-240.8M	-228.2M	-218.4M	-204.8M	-191.8M	-181.8M	-170.2M	-156.2M	-151.2M	-146.1M	-144.8M	-135.2M	-125.1M	-120.8M	-113.5M	-108.3M	-91.8M	-86M	-80.5M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-35.7K	-101.5K	-13.6K	-350K	-5M	-653.7K	0.0	1.4M	0.0	-17.2M	-2.1M	-2.1M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5M	-5M	-5M	-5M	0.0	0.0	0.0
Total Stockholders' Equity	15.2M	20M	24.3M	29M	35.4M	8.8M	5.2M	5.4M	7.9M	987.5K	5.1M	4M	-3.3M	-1.2M	1.1M	4.6M	4.5M	1.7M	1.2M	1.3M
Total Equity	14M	18.9M	23.4M	28.2M	34.8M	8.3M	4.8M	5.2M	7.9M	987.5K	5.1M	4M	-3.3M	-1.2M	1.1M	4.6M	4.5M	1.7M	1.2M	1.3M
Minority Interest	-1.2M	-1.1M	-966K	-847K	-670.5K	-497K	-423K	-251.4K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	16.1M	21.6M	25.5M	30.4M	36.3M	9.5M	6.3M	6.4M	8.8M	5.6M	9.3M	9.1M	5.4M	5.7M	8.6M	10M	9.8M	7.5M	1.9M	1.9M
Total Investments	13.9M	18.7M	22.9M	17.3M	6.6M	2.6M	2.4M	2M	3.5M	750K	2.4M	2.5M	4.2M	5.2M	7.8M	8.8M	8.2M	1.4M	400K	38K
Total Debt	204K	232K	175K	221K	259K	55.2K	0.0	0.0	0.0	4.2M	0.0	0.0	5.5M	32.3K	5M	5M	5M	5M	0.0	0.0
Net Debt	-1M	-1M	-740K	-12.1M	-28.8M	-6.4M	-3.5M	-3.1M	-3.3M	1.7M	-4.4M	-3.4M	4.7M	-307.4K	4.2M	3.9M	3.5M	4.5M	-669.1K	-1.3M
Shares Outstanding	32,913,757	32,913,757	32,913,757	32,913,757	32,913,757	32,913,757	32,913,757	32,913,757	32,913,757	32,913,757	32,913,757	32,913,757	32,913,757	32,913,757	32,913,757	32,913,757	32,913,757	32,913,757	32,913,757	32,913,757

SEC Filings

ANIX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	March 11, 2026	March 10, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	March 09, 2026	January 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 09, 2026	February 09, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	January 28, 2026	January 28, 2026	2026	View Filing
10-K 10-K 2025 FY FY	January 12, 2026	October 31, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 12, 2025	December 11, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	September 10, 2025	July 31, 2025	2025	View Filing
S-3 S-3 N/A	September 10, 2025	September 10, 2025		View Filing
10-Q 10-Q 2025 Q2 Q2	May 28, 2025	April 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	March 21, 2025	March 20, 2025	2025	View Filing

Showing 1 to 10 of 302 filings

Related Guides

Blog Categories

Continue your ANIX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.